Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Prevail Therapeutics Inc. (PRVL)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 | Dec-31-18 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Revenue growth | | | | -100.0% | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | 0.0% |
| Selling, general and administrative [+] | 6.3 | 9.2 | 7.9 | 7.0 | 4.5 | 3.7 | 1.9 | 2.2 |
| General and administrative | 6.3 | 9.2 | 7.9 | 7.0 | 4.5 | 3.7 | 1.9 | 2.2 |
| Research and development | 12.3 | 12.9 | 11.4 | 11.6 | 16.8 | 12.0 | 8.4 | 5.0 |
| EBITDA [+] | -18.5 | -22.0 | -19.2 | -18.5 | -21.2 | -15.6 | -10.3 | -7.2 |
| EBITDA growth | -12.6% | 41.2% | 86.8% | 158.5% | 284.8% | 276.0% | 427.5% | |
| EBITDA margin | | | | | | | | -8221.8% |
| Depreciation and amortization | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| EBIT [+] | -18.6 | -22.2 | -19.3 | -18.6 | -21.3 | -15.7 | -10.3 | -7.2 |
| EBIT growth | -12.5% | 41.4% | 87.2% | 158.4% | 285.7% | 276.1% | 429.4% | |
| EBIT margin | | | | | | | | -8251.7% |
| Interest income | 0.0 | 0.1 | 0.5 | 0.7 | 1.0 | 0.6 | 0.4 | 0.3 |
| Interest income | 0.0 | 0.1 | 0.5 | 0.7 | 1.0 | 0.6 | 0.4 | 0.3 |
| Other income (expense), net | | | 0.2 | | | | | 0.1 |
| Pre-tax income | -18.6 | -22.1 | -18.6 | -17.8 | -20.3 | -15.1 | -9.9 | -6.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -18.6 | -22.1 | -18.6 | -17.8 | -20.3 | -15.1 | -9.9 | -6.7 |
| Net margin | | | | | | | | -7756.3% |
| |
| Basic EPS [+] | ($0.55) | ($0.66) | ($0.56) | ($0.63) | ($0.62) | ($0.58) | ($1.73) | ($1.31) |
| Growth | -10.5% | 14.6% | -67.8% | -52.3% | -37.7% | 197.0% | 163.3% | |
| Diluted EPS [+] | ($0.55) | ($0.66) | ($0.56) | ($0.63) | ($0.62) | ($0.58) | ($1.73) | ($1.31) |
| Growth | -10.5% | 14.6% | -67.8% | -52.3% | -37.7% | 197.0% | 163.3% | |
| |
| Shares outstanding (basic) [+] | 33.6 | 33.5 | 33.3 | 28.5 | 32.9 | 26.2 | 5.7 | 5.1 |
| Growth | 2.4% | 27.7% | 479.5% | 453.8% | 526.6% | 29.0% | 18.1% | |
| Shares outstanding (diluted) [+] | 33.6 | 33.5 | 33.3 | 28.5 | 32.9 | 26.2 | 5.7 | 5.1 |
| Growth | 2.4% | 27.7% | 479.5% | 453.8% | 526.6% | 29.0% | 18.1% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|